WO2000027340A3 - USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF - Google Patents
USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF Download PDFInfo
- Publication number
- WO2000027340A3 WO2000027340A3 PCT/US1999/026696 US9926696W WO0027340A3 WO 2000027340 A3 WO2000027340 A3 WO 2000027340A3 US 9926696 W US9926696 W US 9926696W WO 0027340 A3 WO0027340 A3 WO 0027340A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- fragments
- compositions
- inhibiting angiogenesis
- angiogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20234/00A AU2023400A (en) | 1998-11-12 | 1999-11-12 | Compositions and methods for inhibiting angiogenesis using trna and fragments thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10803698P | 1998-11-12 | 1998-11-12 | |
US60/108,036 | 1998-11-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000027340A2 WO2000027340A2 (en) | 2000-05-18 |
WO2000027340A3 true WO2000027340A3 (en) | 2000-08-17 |
WO2000027340A9 WO2000027340A9 (en) | 2000-11-30 |
Family
ID=22319903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/026696 WO2000027340A2 (en) | 1998-11-12 | 1999-11-12 | USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2023400A (en) |
WO (1) | WO2000027340A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101005299B1 (en) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
LT2578685T (en) * | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HUE058896T2 (en) | 2010-10-01 | 2022-09-28 | Modernatx Inc | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
JP2014511687A (en) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | Engineered nucleic acid delivery and formulation |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (en) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Modified nucleosides, nucleotides and nucleic acids and their application |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (en) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS |
CA2940192C (en) | 2014-02-04 | 2022-09-27 | Thomas Jefferson University | Specific expression of half-trna in cancers |
WO2018119421A1 (en) * | 2016-12-22 | 2018-06-28 | Thomas Jefferson University | Compositions and methods of using rna fragments |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE876739A (en) * | 1978-06-03 | 1979-12-03 | Boehringer Sohn Ingelheim | PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY |
-
1999
- 1999-11-12 AU AU20234/00A patent/AU2023400A/en not_active Abandoned
- 1999-11-12 WO PCT/US1999/026696 patent/WO2000027340A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE876739A (en) * | 1978-06-03 | 1979-12-03 | Boehringer Sohn Ingelheim | PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY |
Non-Patent Citations (4)
Title |
---|
HWANG J.-M. ET AL: "Optic neuropathy associated with mitochondrial tRNA (Leu(UUR)) A3243G mutation.", OPHTHALMIC GENETICS, (1997) 18/2 (101-105)., XP000901440 * |
SMITH P R (REPRINT) ET AL: "Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA (Leu) A to G mutation", OPHTHALMOLOGY, (JUN 1999) VOL. 106, NO. 6, PP. 1101-1108. PUBLISHER: LIPPINCOTT WILLIAMS & WILKINS, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106. ISSN: 0161-6420., QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND (Reprint);UNIV BIRMINGHAM, DEPT MED, BIRMINGHAM, W MIDLANDS, ENGLAND; BIRMINGHAM & MIDLAND EYE HOSP, CITY HOSP NHS TRUST, BIRMIN, XP000901445 * |
SUK, D. ET AL: "Toxicological and antiproliferative effects of N6-(.DELTA.2- isopentenyl)adenosine, a natural component of mammalian transfer RNA", CANCER RES. (1970), 30(5), 1429-36, XP000901623 * |
ZHAO, HUI ET AL: "New role for tRNA and its fragment purified from human urinary bladder carcinoma conditioned medium: Inhibition of endothelial cell growth.", JOURNAL OF CELLULAR BIOCHEMISTRY, (NOV., 1999) VOL. 76, NO. 1, PP. 109-117., XP002135747 * |
Also Published As
Publication number | Publication date |
---|---|
AU2023400A (en) | 2000-05-29 |
WO2000027340A9 (en) | 2000-11-30 |
WO2000027340A2 (en) | 2000-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000027340A3 (en) | USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF | |
CA2426703A1 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
IL155283A0 (en) | Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol | |
WO2002014311A3 (en) | Urea compounds and methods of uses | |
WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
WO2004007457A3 (en) | Substituted benzylamine derivatives and methods of use | |
EP1024145A3 (en) | Novel azalides and methods of making same | |
WO2000056296A3 (en) | Compositions for improving fertility | |
NZ516347A (en) | Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them | |
WO2002080965A3 (en) | Vaccine composition | |
WO2004055006A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
AU3850600A (en) | Dalda analogs and their use | |
WO2001045678A3 (en) | Medicament, a method for its production and the use thereof | |
WO2000066528A3 (en) | Quinones for treatment of diseases | |
MXPA04003027A (en) | Methods for wet granulating azithromycin. | |
WO2002088100A3 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
WO2001076638A3 (en) | Compositions for drug delivery | |
WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
WO2001051044A3 (en) | Substances for use in treating psoriasis | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
WO2002039953A3 (en) | Texaphyrin coordination compounds and uses thereof | |
WO2002059327A3 (en) | Sulfatases and methods of use thereof | |
HUP0104002A3 (en) | Alpha2-antagonists tricyclic delta3-piperidines, process for their producing the pharmaceutical compositions containing them and their use as medicament | |
WO2001060343A3 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers | |
WO2003077874A3 (en) | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |